<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72266">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02008942</url>
  </required_header>
  <id_info>
    <org_study_id>PL-ASA-006</org_study_id>
    <nct_id>NCT02008942</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients</brief_title>
  <acronym>RITE</acronym>
  <official_title>Reliable Inhibition of Thrombocyte Activity: Comparison of PL2200 Aspirin Capsules, 325 mg and Enteric-Coated Aspirin (RITE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PLx Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PLx Pharma</source>
  <oversight_info>
    <authority>United States: MidLands Independent Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine if aspirin from PL2200, an investigational product, gets into the
      blood stream as quickly as enteric coated aspirin, and to test whether PL2200 is able to
      prevent blood clots as effectively as enteric coated aspirin, when administered to patients
      with diabetes
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Pharmacodynamic bioequivalence</measure>
    <time_frame>11 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serial measurements of aspirin anti-platelet activity will be collected over 11 days, and compared between groups, to allow a determination of pharmacodynamic (anti-platelet) bioequivalence between study drugs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic bioequivalence</measure>
    <time_frame>2 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serial measures of aspirin plasma levels will be collected over 2 days, and compared between groups, to allow a determination of pharmacokinetic bioequivalence between study drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>11 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessment and comparison of the incidence of adverse events between treatment groups; changes in clinical laboratory parameters from baseline and between treatment groups; and changes in vital signs from baseline and between treatment groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>PL2200 Aspirin Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PL2200 Aspirin Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enteric-coated aspirin caplets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enteric-coated aspirin caplets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PL2200 Aspirin Capsules</intervention_name>
    <description>325 mg aspirin; once per day for 10 days</description>
    <arm_group_label>PL2200 Aspirin Capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enteric-coated aspirin caplets</intervention_name>
    <description>325 mg aspirin; once per day for 10 days</description>
    <arm_group_label>Enteric-coated aspirin caplets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-Insulin-Dependent Diabetes Mellitus

          -  Adults 21 to 79 years, inclusive

          -  Body mass index between 30 and 40 kg/m2, inclusive

        Exclusion Criteria:

          -  Currently prescribed aspirin or anti-coagulants

          -  Contraindications to aspirin

          -  Significant disease history or active disease other than Non-Insulin-Dependent
             Diabetes Mellitus

          -  Patient requires insulin
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noris Peraita</last_name>
      <phone>305-722-4440</phone>
    </contact>
    <investigator>
      <last_name>Patricia Pardo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PRA Clinical Pharmacology Center</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy Steuart</last_name>
      <phone>913-410-2000</phone>
    </contact>
    <investigator>
      <last_name>Sandra K Willsie, DO, MA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medpace Clinical Pharmacology</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Recruitment</last_name>
      <phone>866-872-2349</phone>
      <email>recruitment@medpace.com</email>
    </contact>
    <investigator>
      <last_name>Lukasz Biernat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 8, 2014</lastchanged_date>
  <firstreceived_date>December 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
